Towler MA, Rush EW, Richardson MK, Williams CL, et al.
Clinics in podiatric medicine and surgery. Date of publication 2018 Jul 1;volume 35(3):357-365.
1. Clin Podiatr Med Surg. 2018 Jul;35(3):357-365. doi: 10.1016/j.cpm.2018.02.006.
Epub 2018 Apr 14.
Randomized, Prospective, Blinded-Enrollment, Head-To-Head Venous Leg Ulcer
Healing Trial Comparing Living, Bioengineered Skin Graft Substitute (Apligraf)
with Living, Cryopreserved, Human Skin Allograft (TheraSkin).
Towler MA(1), Rush EW(2), Richardson MK(2), Williams CL(3).
Author information:
(1)Bon Secours St Francis Wound Healing Center, Suite 100, 131 Commonwealth
Drive, Greenville, SC 29615, USA. Electronic address: mtowler@charter.net.
(2)Bon Secours St Francis Wound Healing Center, Suite 100, 131 Commonwealth
Drive, Greenville, SC 29615, USA.
(3)Department of Mathematical Sciences, Center for Excellence in Mathematics and
Science Education, Clemson University, 0-323 Martin Hall, Clemson, SC 29634-0975,
USA.
Chronic venous leg ulcers are responsible for significant morbidity and health
care costs worldwide. This pilot study evaluated the effectiveness 2 biologically
active grafts, TheraSkin and Apligraf, in conjunction with compression therapy.
The study, not industry-sponsored, was designed and conducted as a prospective,
head-to-head, single-site, randomized clinical trial to assess differences in
healing rates, adverse outcomes, and treatment costs. The healing rates were
different but not statistically significant, there were no adverse outcomes, and
TheraSkin averaged $2495.33 and Apligraf averaged $4316.67 per subject. This
suggests that TheraSkin may provide equivalent or superior outcomes to Apligraf
while reducing costs.
Copyright © 2018 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.cpm.2018.02.006
PMID: 29861018
